Opportunities in somatostatin research: Biological, chemical and therapeutic aspects

被引：465

作者：

Weckbecker, G ^{[1
]}

Lewis, I ^{[1
]}

Albert, R ^{[1
]}

Schmid, HA ^{[1
]}

Hoyer, D ^{[1
]}

Bruns, C ^{[1
]}

机构：

[1] Novartis Pharma AG, Novartis Inst Biomed Res, Transplantat & Immunol, CH-4002 Basel, Switzerland

来源：

NATURE REVIEWS DRUG DISCOVERY | 2003年 / 2卷 / 12期

关键词：

D O I：

10.1038/nrd1255

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Somatostatins - also known as somatotropin-release inhibiting factors (SRIFs) - are a family of cyclopeptides that have broad inhibitory effects on the secretion of hormones such as growth hormone, insulin and glucagon. These effects have formed the basis for the clinical use of SRIF analogues in the treatment of acromegaly and endocrine tumours. The discovery of the five SRIF receptor subtypes in the 1990s further enhanced our understanding of the biological roles of SRIFs, and paved the way for new therapeutic opportunities. Here we review recent advances in SRIF biology, the chemistry of SRIF agonists and antagonists, and the therapeutic potential of such compounds in a wide range of established and novel indications.

引用

页码：999 / 1017

页数：19

共 226 条

[1]

ADAMS RL, 2003, END SOC M JUN

[2] Novel long-acting somatostatin analog with endocrine selectivity: Potent suppression of growth hormone but not of insulin [J].

Afargan, M ;

Janson, ET ;

Gelerman, G ;

Rosenfeld, R ;

Ziv, O ;

Karpov, O ;

Wolf, A ;

Bracha, M ;

Shohat, D ;

Liapakis, G ;

Gilon, C ;

Hoffman, A ;

Stephensky, D ;

Oberg, K .

ENDOCRINOLOGY, 2001, 142 (01) :477-486

[3] PHOSPHOLIPASE-C ACTIVATION AND CA2+ MOBILIZATION BY CLONED HUMAN SOMATOSTATIN RECEPTOR SUBTYPES-1-5, IN TRANSFECTED COS-7 CELLS [J].

AKBAR, M ;

OKAJIMA, F ;

TOMURA, H ;

MAJID, MA ;

YAMADA, Y ;

SEINO, S ;

KONDO, Y .

FEBS LETTERS, 1994, 348 (02) :192-196

[4] Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis [J].

Albini, A ;

Florio, T ;

Giunciuglio, D ;

Masiello, L ;

Carlone, S ;

Corsaro, A ;

Thellung, S ;

Cai, T ;

Noonan, DM ;

Schettini, G .

FASEB JOURNAL, 1999, 13 (06) :647-655

[5] Discovery of a novel non-peptide somatostatin agonist with SST4 selectivity [J].

Ankersen, M ;

Crider, M ;

Liu, SQ ;

Ho, B ;

Andersen, HS ;

Stidsen, C .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1998, 120 (07) :1368-1373

[6] Treatment of neuroendocrine GEP tumours with somatostatin analogues - A review [J].

Arnold, R ;

Simon, B ;

Wied, M .

DIGESTION, 2000, 62 :84-91

[7] Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European acute bleeding oesophageal variceal episodes (ABOVE) randomised trial [J].

Avgerinos, A ;

Nevens, F ;

Raptis, S ;

Fevery, J ;

Armonis, A ;

Manolakopoulos, S ;

Poulianos, G ;

Tzathas, C ;

Katsaros, D ;

Soutos, D ;

Zacharopoulose, A ;

Adler, M ;

Bourgeois, N ;

Bac, DJ ;

VanBuuren, HR ;

Decruyenaere, J ;

Elewaut, A ;

Deman, M ;

Lepoutre, L ;

VanderSpek, P ;

Hautekeete, M ;

Reynaert, H ;

Buyse, M ;

Ritter, L ;

Burtin, B ;

Darcis, T ;

Ioannou, J ;

Natens, J ;

Natens, O .

LANCET, 1997, 350 (9090) :1495-1499

[8] Effects of the somatostatin analogue octreotide on renal function in conscious diabetic rats [J].

Bak, M ;

Thomsen, K ;

Flyvbjerg, A .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (10) :2002-2007

[9] [IN-111-DTPA-D-PHE1]-OCTREOTIDE, A POTENTIAL RADIOPHARMACEUTICAL FOR IMAGING OF SOMATOSTATIN RECEPTOR-POSITIVE TUMORS - SYNTHESIS, RADIOLABELING AND INVITRO VALIDATION [J].

BAKKER, WH ;

ALBERT, R ;

BRUNS, C ;

BREEMAN, WAP ;

HOFLAND, LJ ;

MARBACH, P ;

PLESS, J ;

PRALET, D ;

STOLZ, B ;

KOPER, JW ;

LAMBERTS, SWJ ;

VISSER, TJ ;

KRENNING, EP .

LIFE SCIENCES, 1991, 49 (22) :1583-1591

[10] Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels [J].

Barkan, AL ;

Dimaraki, EV ;

Jessup, SK ;

Symons, KV ;

Ermolenko, M ;

Jaffe, CA .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05) :2180-2184

← 1 2 3 4 5 6 7 8 9 10 →